small molecule

ZEGFROVY

SUNVOZERTINIB

Loss of exclusivityJanuary 2039latest FDA-listed patent expiry

CompanyDIZAL PHARMACEUTICAL CO LTD

Drug detail

Brand name	ZEGFROVY
Active ingredient	SUNVOZERTINIB
Strength	150MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	July 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
11504375	January 2039	substance, product
11896597	January 2039	substance, product
11007198	January 2039	substance, product

Regulatory exclusivity

Code	Expires
NCE	July 2030

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from DIZAL PHARMACEUTICAL CO LTD